麻豆传媒

The results of two clinical trials presented at the recent Society of Gynecologic Oncology (SGO) annual meeting showed that adding immunotherapy to standard chemotherapy resulted in significantly longer progression-free survival (PFS) among patients with advanced or recurrent endometrial cancer.

In this exclusive 麻豆传媒 video, Paul DiSilvestro, MD, director of the Program in Women's Oncology at Women & Infants Hospital of Rhode Island, discusses the importance of the and trials.

Following is a transcript of his remarks:

I can't really do this interview without talking about yesterday afternoon's presentations, and that's the role of immunotherapy and endometrial cancer.

So we had two landmark studies present in a special session. Both of them hit the mark. They just hit it out of the park for showing the benefit of adding immunotherapy to chemotherapy for women with advanced and recurrent endometrial cancer. And this has really been an unmet need for us in our discipline and having those results and having so many people here to listen to those results.

And hopefully we'll see the approvals in the near future and begin to incorporate it into what we do every day.

Comment